
BMJ appoints US managing director
pharmafile | August 9, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | BMJ, Campbell
Medical journal BMJ has hired Glen Campbell from Elsevier to be its US managing director.
Campbell joins BMJ on 2 September from Elsevier where he was an executive vice president for Society Business Development, STM Journals. He has spent most of his working life at the firm, where up until his most recent role, he worked in its Health Sciences Division.
More recently, in his role as EVP for Global Medical Research, Campbell was responsible for the worldwide journals programme of Elsevier Health Sciences, overseeing more than 400 titles.
BMJ chief executive Tim Brooks said: “Glen is a most experienced professional, who brings a lifelong knowledge of medical publishing, and unrivalled contacts in the US health sector. His appointment follows that of Anand Ekambaram to the corresponding role in India, announced last month.”
Campbell added: “I am thrilled to be joining BMJ to work on the expansion of its US business. With the medical research journal in a period of evolution, The BMJ itself has been a dynamic and creative innovator in both content and business models.
“BMJ Clinical Evidence and BMJ Best Practice have also broken new ground in providing clinicians with evidence-based information and knowledge. There is boundless opportunity in the US, and I look forward to building on BMJ’s current success in this market to realise its full potential.”
Related Content

Almost half of all cancer drug trials show bias and exaggeration
New research on clinical trials between 2014 and 2016 raise “serious concerns about low standards” …

Investigation questions Xarelto trial data accuracy
The ROCKET-AF trial, the pivotal trial of the top-selling anti-clotting drug Xarelto, could have been …

Governments and industry ‘combining to stall drug development’
Both government and industry practices are responsible for the innovation deficit in the pharmaceutical sector, …






